Multivariate analysis demonstrated that age greater than 60 years, the presence of B symptoms, elevated β2M level levels, absence of Rituximab therapy, and p53/PD-L1 co-expression were independent indicators of inferior OS and PFS in DLBCL patients (Fig. 3). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.